Becton, Dickinson and Company (BDX) To Go Ex-Dividend on March 10th

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Tuesday, January 27th. Investors of record on Tuesday, March 10th will be given a dividend of 1.05 per share by the medical instruments supplier on Tuesday, March 31st. This represents a c) annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, March 10th.

Becton, Dickinson and Company has raised its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 26.9%.

Becton, Dickinson and Company Price Performance

BDX opened at $167.31 on Friday. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a 50 day moving average of $193.26 and a two-hundred day moving average of $191.22. The company has a market cap of $47.64 billion, a P/E ratio of 27.29, a P/E/G ratio of 12.12 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the previous year, the business posted $3.43 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Analyst Ratings Changes

BDX has been the topic of several analyst reports. Barclays assumed coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price on the stock. Citigroup lowered their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Jefferies Financial Group reduced their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Wells Fargo & Company dropped their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.